Our
company

AEVA is a biotech company, aiming at addressing unmet medical needs, with multimodal molecular diagnostic approaches. The acronym of the name stands for Advanced Extracellular Vesicle Applications, pointing out the idea of exploiting extracellular vesicles to identify innovative clinical applications and to advance liquid biopsy testing.

A group of researchers from CIBIO (Department of Cellular, Computational and Integrative Biology of the University of Trento) founded the company in December 2019. The researchers are all inventors of the patent protecting AEVA core technology.

An exclusive license and research collaboration agreement is made by and between AEVA S.r.l. (Trento, Italy) and EVBiome Inc. (Palo Alto, California, USA) for the exclusive license of AEVA patent related to isolation and analysis of extracellular vesicles, furthermore, AEVA agrees to conduct additional research and development for EVBiome in the field of early disease diagnosis in Oncology as well as neurodegenerative conditions.